Get started
Author

Ohad Amit

Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease
2003 · Elizabeth Gamble, Diana C. Grootendorst, et al. · American Journal of Respiratory and Critical Care Medicine · 210
Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study
2001 · Christopher H Compton, Jason Gubb, et al. · The Lancet · 208
Cilomilast for COPD
2006 · Stephen I. Rennard, Neil Schachter, et al. · CHEST Journal · 114
Blinded independent central review of progression in cancer clinical trials: Results from a meta-analysis
2011 · O. Amit, F. Mannino, et al. · European Journal of Cancer · 107
Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer
2008 · D. Slamon, H. L. Gomez, et al. · Journal of Clinical Oncology · 84
Graphical approaches to the analysis of safety data from clinical trials
2007 · Ohad Amit, Richard M. Heiberger, et al. · Pharmaceutical Statistics · 81
Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group
2011 · A.M. Stone, W. Bushnell, et al. · European Journal of Cancer · 56
Blinded Independent Central Review of the Progression-Free Survival Endpoint
2010 · Ohad Amit, Will Bushnell, et al. · The Oncologist · 40
Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE’s STAT-Net
2018 · Marlieke E A de Kraker, Harriet Sommer, et al. · Clinical Infectious Diseases · 35
PDF
Cilomilast for COPD: Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4
2006 · S.I. Rennard, N. Schachter, et al. · Respiratory Medicine COPD Update · 29
DuP 532, an angiotensin II receptor antagonist: First administration and comparison with losartan*
1997 · Michael R. Goldberg, Man-Wai Lo, et al. · Clinical Pharmacology & Therapeutics · 8
Evaluation of Discordance Measures in Oncology Studies with Blinded Independent Central Review of Progression-Free Survival Using an Observational Error Model
2013 · F. V. Mannino, O. Amit, et al. · Journal of Biopharmaceutical Statistics · 4
Graphics for Safety Analysis
2012 · Peter W. Lane, Ohad Amit · Springer eBooks · 1
P1.01-110 Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol
2019 · D. Spigel, M. Garassino, et al. · Journal of Thoracic Oncology
PDF
Efficiencies of Platform Trials
2018 · Satrajit Roychoudhury, Ohad Amit · Chapman & Hall/CRC eBooks
Introduction
2018 · Ohad Amit · Chapman & Hall/CRC eBooks
Utilizing a Clinical Utility Index in a Phase 2, Randomized, Bayesian Response-Adaptive Design to Study the Efficacy and Safety of Gepotidacin (GSK2140944) in Patients With Acute Bacterial Skin and Skin Structure Infections
2016 · Teri Ashton, Ohad Amit, et al. · Open Forum Infectious Diseases
PDF
Par15: Comparison of Health Care Resource Utilization of Copd Patients on Cilomilast, 15 Mg Bid Versus Placebo
2001 · I Bagchi, A Bakst, et al. · Value in Health
PDF
Works count: 18
Citation count: 977
H-index: 10
I10-index: 10
Year
Topic
Type